docos-13-enoic acid-anhydride | 871893-44-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: docos-13-enoic acid-anhydride
• 英文别名: Docos-13-ensaeure-anhydrid；Docos-13-enoyl Docos-13-enoate
• CAS: 871893-44-6
• 化学式: C₄₄H₈₂O₃
• 分子量: 659.133
• InChiKey: LVWSCSGKAPKSBZ-UHFFFAOYSA-N

物化性质

• 沸点：
  682.3±24.0 °C(Predicted)
• 密度：
  0.887±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  19.2
• 重原子数：
  47
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.863
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  docos-13-enoic acid-anhydride 在 硝酸 作用下， 生成 brassidic acid anhydride
  参考文献：
  名称：

  Holde; Zadek, Chemische Berichte, 1923, vol. 56, p. 2056

  摘要：

  DOI：
• 作为产物：
  描述：

  芥酸 、 乙酸酐 生成 docos-13-enoic acid-anhydride
  参考文献：
  名称：

  Albitzki, Zhurnal Russkago Fiziko-Khimicheskago Obshchestva, 1899, vol. 31, p. 103

  摘要：

  DOI：

文献信息

• PREPARATION OF AMINO ACID-FATTY ACID ANHYDRIDES
  申请人：MacDougall Joseph

  公开号：US20080200725A1

  公开（公告）日：2008-08-21

  The present invention describes compounds produced from an amino acid molecule and a fatty acid molecule. The compounds being in the form of amino-fatty acid compounds being bound by an anhydride linkage, or mixtures thereof made by reacting amino acids or derivatives thereof with an appropriate fatty acid previously reacted with a thionyl halide. The administration of such molecules provides supplemental amino acids with enhanced bioavailability and the additional benefits conferred by the specific fatty acid.

  本发明描述了由氨基酸分子和脂肪酸分子产生的化合物。这些化合物采用酐键连接的氨基-脂肪酸化合物形式存在，或者是由氨基酸或其衍生物与预先经过硫酰卤化物反应的适当脂肪酸混合物制成的。这些分子的使用提供了增强生物利用度的补充氨基酸以及特定脂肪酸所赋予的附加益处。
• Preparation of amino acid-fatty acid anhydrides
  申请人：MacDougall Joseph

  公开号：US20080281113A1

  公开（公告）日：2008-11-13

  The present invention describes compounds produced from an amino acid molecule and a fatty acid molecule. The compounds being in the form of amino-fatty acid compounds being bound by an anhydride linkage, or mixtures thereof made by reacting amino acids or derivatives thereof with an appropriate fatty acid previously reacted with a thionyl halide. The administration of such molecules provides supplemental amino acids with enhanced bioavailability and the additional benefits conferred by the specific fatty acid.

  本发明描述了由氨基酸分子和脂肪酸分子产生的化合物。这些化合物采用酐键连接，形成氨基脂肪酸化合物，或者由氨基酸或其衍生物与事先与硫酰卤反应的适当脂肪酸混合而成。这些分子的使用提供了增强生物利用度的补充氨基酸和特定脂肪酸所赋予的额外益处。
• Nalbuphine esters and long-acting pharmaceutical compositions containing them
  申请人：NATIONAL SCIENCE COUNCIL

  公开号：EP0615756A1

  公开（公告）日：1994-09-21

  This invention is related to novel long acting analgesic Nalbuphine prodrugs including a process for the preparation, and phamaceutical composition comprising nalbuphine prodrugs. These prodrugs are long-acting injectable analgesics when given intramuscularly, subcutaneously, intracerebroventricularly or in the mammal via the oral, sublingual, buccally or percutaneous route or other administration routes. The chemical structure of nalbuphine prodrugs on this invention is shown in figure (1), while R group is R'CO, the R' is selected from the groups consisting of (a) straight chain alkyl group, (b) branched chain alkyl group, (c) straight chain alkyl group on benzene (d) branched chain alkyl group on benzene, wherein the straight chain branched chain is represents the saturated or unsaturated C1-40 alkyl groups. The nalbuphine prodrugs were synthesized by esterification of nalbuphine base with acid chlorides or acid anhydrides of saturated fatty acids or unsaturated fatty acids with various lengths. For therapeutic use, the prodrugs can be formulated into different dosage forms, such as oily injectable or oral preparations, etc. for spinal marrow, intramuscular, or intracerebroventricular injection routes, upon oral administration they have less of a first -pass effect and better bioavailability.

  本发明涉及新型长效镇痛药纳布啡原药，包括纳布啡原药的制备工艺和药物组合物。这些原药是长效注射镇痛药，可通过肌肉注射、皮下注射、脑室内注射或哺乳动物口服、舌下含服、颊部含服、经皮或其他给药途径给药。本发明的纳布啡原药化学结构如图（1）所示，R基为R'CO，R'选自(a)直链烷基、(b)支链烷基、(c)苯上直链烷基(d)苯上支链烷基组成的基团，其中直链支链代表饱和或不饱和的C1-40烷基。 纳布啡原药是通过纳布啡碱与不同长度的饱和脂肪酸或不饱和脂肪酸的酸氯化物或酸酐酯化合成的。原药可配制成不同的剂型，如油性注射剂或口服制剂等，用于脊髓、肌肉或脑室内注射，口服后的首过效应较小，生物利用度较高。
• Composition comprising esters of lignin and oil or fatty acids
  申请人：REN FUEL K2B AB

  公开号：US10030147B2

  公开（公告）日：2018-07-24

  The present invention relates to a composition comprising a carrier liquid and lignin or lignin derivatives solubilized in said carrier liquid; wherein at least one of the hydroxyl groups of the lignin or lignin derivatives have been substituted with ester groups forming esterified lignin or lignin derivatives. The composition may be used for preparing fuels or lubricants.

  本发明涉及一种组合物，该组合物包含载液和溶解在所述载液中的木质素或木质素衍生物；其中木质素或木质素衍生物的至少一个羟基已被酯基取代，形成酯化木质素或木质素衍生物。该组合物可用于制备燃料或润滑油。
• Composition comprising derivatized lignin for fuel production
  申请人：Ren Fuel K2B AB

  公开号：US10676688B2

  公开（公告）日：2020-06-09

  The present invention relates to a composition comprising lignin and a solvent where the lignin is functionalized with an ether group.

  本发明涉及一种由木质素和溶剂组成的组合物，其中木质素被一个醚基官能化。